Inflammasomes and type 2 diabetes: An updated systematic review

Immunology Letters

Volumn 192, Issue , 2017, Pages 97-103

  Sepehri, Zahra ^a   Kiani, Zohre ^a   Afshari, Mahdi ^a   Kohan, Farhad ^a   Dalvand, Azadeh ^b   Ghavami, Saeid ^c,d  

^a ZABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Caspase 1; IL 18; IL 1 ; Inflammasomes; Lysosome; Type 2 diabetes; Unfolded protein response

Indexed keywords

BIOLOGICAL FACTOR; CRYOPYRIN; DAMAGE ASSOCIATED MOLECULAR PATTERN; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; NEURONAL APOPTOSIS INHIBITORY PROTEIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; NLRP1 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

CELL STRESS; DIABETIC COMPLICATION; ENZYME ACTIVATION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OLIGOMERIZATION; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; UPREGULATION; ANIMAL; APOPTOSIS; IMMUNOLOGY; INFLAMMATION; METABOLISM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASE 1; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMASOMES; INFLAMMATION; INTERLEUKIN-18; INTERLEUKIN-1BETA; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; SIGNAL TRANSDUCTION;

EID: 85032805621     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2017.10.010     Document Type: Review

References (97)

1. Xu, Y., Huang, Q., Zhang, W., Wang, Y., Zeng, Q., He, C., et al. Decreased expression levels of Nurr1 are associated with chronic inflammation in patients with type 2 diabetes. Mol. Med. Rep. 12 (2015), 5487–5493.
2. Isailovic, N., Daigo, K., Mantovani, A., Selmi, C., Interleukin-17 and innate immunity in infections and chronic inflammation. J. Autoimmun. 60 (2015), 1–11.
3. Bagheri, V., Askari, A., Arababadi, M.K., Kennedy, D., Can Toll-Like Receptor (TLR) 2 be considered as a new target for immunotherapy against hepatitis B infection. Hum. Immunol. 75 (2014), 549–554.
4. Gaudet, R.G., Guo, C.X., Molinaro, R., Kottwitz, H., Rohde, J.R., Dangeard, A.S., et al. Innate recognition of intracellular bacterial growth is driven by the TIFA-dependent cytosolic surveillance pathway. Cell Rep. 19 (2017), 1418–1430.
5. Karimi-Googheri, M., Arababadi, M.K., TLR3 plays significant roles against hepatitis B virus. Mol. Biol. Rep. 41 (2014), 3279–3286.
6. Herwald, H., Egesten, A., On PAMPs and DAMPs. J. Innate Immun. 8 (2016), 427–428.
7. Tang, D., Kang, R., Coyne, C.B., Zeh, H.J., Lotze, M.T., PAMPs and DAMPs: signal 0 s that spur autophagy and immunity. Immunol. Rev. 249 (2012), 158–175.
8. Askari, A., Nosratabadi, R., Khaleghinia, M., Zainodini, N., Kennedy, D., Shabani, Z., et al. Evaluation of NLRC4, NLRP1and NLRP3, as components of inflammasomes, in chronic HBV infected patients. Vir Immunol, 2016 article in press.
9. Osborn, O., Gram, H., Zorrilla, E.P., Conti, B., Bartfai, T., Insights into the roles of the inflammatory mediators IL-1, IL-18 and PGE2 in obesity and insulin resistance. Swiss Med. Week, 138, 2008, 665.
10. Zalinger, Z.B., Elliott, R., Weiss, S.R., Role of the inflammasome-related cytokines Il-1 and Il-18 during infection with murine coronavirus. J. Neurovirol., 2017.
11. Guo, H., Callaway, J.B., Ting, J.P., Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat. Med. 21 (2015), 677–687.
12. Pirola, L., Ferraz, J.C., Role of pro- and anti-inflammatory phenomena in the physiopathology of type 2 diabetes and obesity. World J. Biol. Chem. 8 (2017), 120–128.
13. Masters, S.L., Dunne, A., Subramanian, S.L., Hull, R.L., Tannahill, G.M., Sharp, F.A., et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat. Immunol. 11 (2010), 897–904.
14. Karstoft, K., Pedersen BK. Exercise and type 2 diabetes: focus on metabolism and inflammation. Immunol. Cell Biol. 94 (2016), 146–150.
15. Elf, S.E., Chen, J., Targeting glucose metabolism in patients with cancer. Cancer 120 (2014), 774–780.
16. Trikkalinou, A., Papazafiropoulou, A.K., Melidonis A. Type 2 diabetes and quality of life. World J. Diabetes 8 (2017), 120–129.
17. Lascar, N., Brown, J., Pattison, H., Barnett, A.H., Bailey, C.J., Bellary, S., Type 2 diabetes in adolescents and young adults. Lancet Diabetes Endocrinol., 2017 pii: S2213-8587(17)30186-9.
18. Alexandraki, K.I., Piperi, C., Ziakas, P.D., Apostolopoulos, N.V., Makrilakis, K., Syriou, V., et al. Cytokine secretion in long-standing diabetes mellitus type 1 and 2: associations with low-grade systemic inflammation. J. Clin. Immunol. 28 (2008), 314–321.
19. Valencia, W.M., Florez, H., How to prevent the microvascular complications of type 2 diabetes beyond glucose control. BMJ, 356, 2017, i6505.
20. Boni-Schnetzler, M., Donath, M.Y., How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes. Br. J. Clin. Pharmacol. 76 (2013), 263–268.
21. Barag, S.H., Insulin therapy for management of type 2 diabetes mellitus: strategies for initiation and long-term patient adherence. J. Am. Osteopath. Assoc. 111 (2011), S13–19.
22. Chen, G.Y., Role of Nlrp6 and Nlrp12 in the maintenance of intestinal homeostasis. Eur. J. Immunol. 44 (2014), 321–327.
23. Caroline, M., Anjos, V., Nogueira-Machado, J., Inflammasome as a new therapeutic target for diabetic complications. Recent Pat Endocr Metab Immune Drug Discov, 2016 article in press.
24. Schroder, K., Tschopp, J., The inflammasomes. Cell 140 (2010), 821–832.
25. Proell, M., Gerlic, M., Mace, P.D., Reed, J.C., Riedl, S.J., The CARD plays a critical role in ASC foci formation and inflammasome signalling. Biochem. J. 449 (2013), 613–621.
26. Lu, W.L., Song, D.Z., Yue, J.L., Wang, T.T., Zhou, X.D., Zhang, P., et al. NLRP3 inflammasome may regulate inflammatory response of human periodontal ligament fibroblasts in an apoptosis-associated speck-like protein containing a CARD (ASC)-dependent manner. Int. Endod. J. 50 (2017), 967–975.
27. Zhao, Y., Shao, F., The NAIP-NLRC4 inflammasome in innate immune detection of bacterial flagellin and type III secretion apparatus. Immunol. Rev. 265 (2015), 85–102.
28. Yang, S.J., Shao, G.F., Chen, J.L., Gong, J., The NLRP3 inflammasome: an important driver of neuroinflammation in hemorrhagic stroke. Cell. Mol. Neurobiol., 2017.
29. Kunnas, T., Maatta, K., Nikkari, S.T., NLR family pyrin domain containing 3 (NLRP3) inflammasome gene polymorphism rs7512998 (C>T) predicts aging-related increase of blood pressure, the TAMRISK study. Immun. Ageing, 12, 2015, 19.
30. Pontillo, A., Brandao, L., Guimaraes, R., Segat, L., Araujo, J., Crovella, S., Two SNPs in NLRP3 gene are involved in the predisposition to type-1 diabetes and celiac disease in a pediatric population from northeast Brazil. Autoimmunity 43 (2010), 583–589.
31. Lamkanfi, M., Kanneganti, T.D., Nlrp3: an immune sensor of cellular stress and infection. Int. J. Biochem. Cell Biol. 42 (2010), 792–795.
32. Lamkanfi, M., Dixit, V.M., Inflammasomes: guardians of cytosolic sanctity. Immunol. Rev. 227 (2009), 95–105.
33. Patel, S., Inflammasomes, the cardinal pathology mediators are activated by pathogens, allergens and mutagens: a critical review with focus on NLRP3. Biomed. Pharmacother. 92 (2017), 819–825.
34. Harris, J., Lang, T., Thomas, J.P.W., Sukkar, M.B., Nabar, N.R., Kehrl JH. autophagy and inflammasomes. Mol. Immunol. 86 (2017), 10–15.
35. He, Y., Hara, H., Mechanism, Nunez G., Regulation of NLRP3 inflammasome activation. Trends Biochem. Sci. 41 (2016), 1012–1021.
36. Asmussen, A., Fink, K., Busch, H.J., Helbing, T., Bourgeois, N., Bode, C., et al. Inflammasome and toll-like receptor signaling in human monocytes after successful cardiopulmonary resuscitation. Crit. Care, 20, 2016, 170.
37. Ringseis, R., Eder, K., Mooren, F.C., Kruger, K., Metabolic signals and innate immune activation in obesity and exercise. Exerc. Immunol. Rev. 21 (2015), 58–68.
38. Ferrero-Miliani, L., Nielsen, O.H., Andersen, P.S., Girardin, S.E., Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation. Clin. Exp. Immunol. 147 (2007), 227–235.
39. Liston, A., Masters, S.L., Homeostasis-altering molecular processes as mechanisms of inflammasome activation. Nat. Rev. Immunol. 17 (2017), 208–214.
40. Kesavardhana, S., Kanneganti, T.D., Mechanisms governing inflammasome activation, assembly and pyroptosis induction. Int. Immunol., 2017.
41. Prochnicki, T., Latz, E., Inflammasomes on the crossroads of innate immune recognition and metabolic control. Cell Metab. 26 (2017), 71–93.
42. Choi, A.J., Ryter, S.W., Inflammasomes: molecular regulation and implications for metabolic and cognitive diseases. Mol. Cells 37 (2014), 441–448.
43. Ghavami, S., Yeganeh, B., Stelmack, G.L., Kashani, H.H., Sharma, P., Cunnington, R., et al. Apoptosis, autophagy and ER stress in mevalonate cascade inhibition-induced cell death of human atrial fibroblasts. Cell. Death Dis., 3, 2012, e330.
44. Ghavami, S., Eshraghi, M., Kadkhoda, K., Mutawe, M.M., Maddika, S., Bay, G.H., et al. Role of BNIP3 in TNF-induced cell death–TNF upregulates BNIP3 expression. Biochim. Biophys. Acta 1793 (2009), 546–560.
45. Orlowski, G.M., Sharma, S., Colbert, J.D., Bogyo, M., Robertson, S.A., Kataoka, H., et al. Frontline Science: multiple cathepsins promote inflammasome-independent, particle-induced cell death during NLRP3-dependent IL-1beta activation. J. Leukoc. Biol. 102 (2017), 7–17.
46. Orlowski, G.M., Colbert, J.D., Sharma, S., Bogyo, M., Robertson, S.A., Rock, K.L., Multiple cathepsins promote pro-IL-1beta synthesis and NLRP3-Mediated IL-1beta activation. J. Immunol. 195 (2015), 1685–1697.
47. Katsnelson, M.A., Lozada-Soto, K.M., Russo, H.M., Miller, B.A., Dubyak, G.R., NLRP3 inflammasome signaling is activated by low-level lysosome disruption but inhibited by extensive lysosome disruption: roles for K+ efflux and Ca2+ influx. Am. J. Physiol. Cell Physiol. 311 (2016), C83–C100.
48. Zhou, R., Tardivel, A., Thorens, B., Choi, I., Tschopp, J., Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11 (2010), 136–140.
49. Mastrocola, R., Collino, M., Penna, C., Nigro, D., Chiazza, F., Fracasso, V., et al. Maladaptive modulations of NLRP3 inflammasome and cardioprotective pathways are involved in diet-Induced exacerbation of myocardial Ischemia/Reperfusion injury in mice. Oxid. Med. Cell. Longev., 2016, 2016, 3480637.
50. Mokarram, P., Albokashy, M., Zarghooni, M., Moosavi, M.A., Sepehri, Z., Chen, Q.M., et al. New frontiers in the treatment of colorectal cancer: autophagy and the unfolded protein response as promising targets. Autophagy 13 (2017), 781–819.
51. Iranpour, M., Moghadam, A.R., Yazdi, M., Ande, S.R., Alizadeh, J., Wiechec, E., et al. Apoptosis, autophagy and unfolded protein response pathways in Arbovirus replication and pathogenesis. Expert Rev. Mol. Med., 18, 2016, e1.
52. Yeganeh, B., Jager, R., Gorman, A.M., Samali, A., Induction of Autophagy: Role of Endoplasmic Reticulum Stress and Unfolded Protein Response. Hayat, M.A., (eds.) Autophagy: Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging, 2015, Elsevier Inc., 91–101.
53. Menu, P., Mayor, A., Zhou, R., Tardivel, A., Ichijo, H., Mori, K., et al. ER stress activates the NLRP3 inflammasome via an UPR-independent pathway. Cell Death Dis., 3, 2012, e261.
54. Grant, R.W., Dixit, V.D., Mechanisms of disease: inflammasome activation and the development of type 2 diabetes. Front. Immunol., 4, 2013, 50.
55. Caprio, S., Perry, R., Kursawe, R., Adolescent obesity and insulin resistance roles of ectopic fat accumulation and adipose inflammation. Gastroenterology 152 (2017), 1638–1646.
56. Abderrazak, A., Syrovets, T., Couchie, D., El Hadri, K., Friguet, B., Simmet, T., et al. NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biol. 4 (2015), 296–307.
57. Ruscitti, P., Cipriani, P., Di Benedetto, P., Liakouli, V., Berardicurti, O., Carubbi, F., et al. Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3 (NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. Clin. Exp. Immunol. 182 (2015), 35–44.
58. Lee, H.M., Kim, J.J., Kim, H.J., Shong, M., Ku, B.J., Jo, E.K., Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 62 (2013), 194–204.
59. Katsiki, N., Athyros, V.G., Karagiannis, A., Mikhailidis DP. statins and type 2 diabetes mellitus: an update after 1 year. Curr. Pharm. Des. 22 (2016), 2723–2725.
60. Henriksbo, B.D., Lau, T.C., Cavallari, J.F., Denou, E., Chi, W., Lally, J.S., et al. Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance. Diabetes 63 (2014), 3742–3747.
61. Esser, N., L'Homme, L., De Roover, A., Kohnen, L., Scheen, A.J., Moutschen, M., et al. Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia 56 (2013), 2487–2497.
62. Dangwal, S., Stratmann, B., Bang, C., Lorenzen, J.M., Kumarswamy, R., Fiedler, J., et al. Impairment of wound healing in patients with type 2 diabetes mellitus influences circulating MicroRNA patterns via inflammatory cytokines. Arterioscler. Thromb. Vasc. Biol. 35 (2015), 1480–1488.
63. Bitto, A., Altavilla, D., Pizzino, G., Irrera, N., Pallio, G., Colonna, M.R., et al. Inhibition of inflammasome activation improves the impaired pattern of healing in genetically diabetic mice. Br. J. Pharmacol. 171 (2014), 2300–2307.
64. Juliana, C., Fernandes-Alnemri, T., Kang, S., Farias, A., Qin, F., Alnemri, E.S., Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J. Biol. Chem. 287 (2012), 36617–36622.
65. Oslowski, C.M., Hara, T., O'Sullivan-Murphy, B., Kanekura, K., Lu, S., Hara, M., et al. Thioredoxin-interacting protein mediates ER stress-induced β cell death through initiation of the inflammasome. Cell Metabol 16 (2012), 265–273.
66. Dixit, V.D., Nlrp3 inflammasome activation in type 2 diabetes: is it clinically relevant. Diabetes 62 (2013), 22–24.
67. Vandanmagsar, B., Youm, Y.H., Ravussin, A., Galgani, J.E., Stadler, K., Mynatt, R.L., et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17 (2011), 179–188.
68. Pejnovic, N.N., Pantic, J.M., Jovanovic, I.P., Radosavljevic, G.D., Milovanovic, M.Z., Nikolic, I.G., et al. Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic islets. Diabetes 62 (2013), 1932–1944.
69. Jeftic, I., Jovicic, N., Pantic, J., Arsenijevic, N., Lukic, M.L., Pejnovic, N., Galectin-3 ablation enhances liver steatosis, but attenuates inflammation and IL-33-Dependent fibrosis in obesogenic mouse model of nonalcoholic steatohepatitis. Mol. Med. 21 (2014), 453–465.
70. Jourdan, T., Godlewski, G., Cinar, R., Bertola, A., Szanda, G., Liu, J., et al. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat. Med. 19 (2013), 1132–1140.
71. Kim, S.M., Lee, S.H., Kim, Y.G., Kim, S.Y., Seo, J.W., Choi, Y.W., et al. Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy. Am. J. Physiol. Renal. Physiol. 308 (2015), F993–F1003.
72. Solini, A., Menini, S., Rossi, C., Ricci, C., Santini, E., Blasetti Fantauzzi, C., et al. The purinergic 2X7 receptor participates in renal inflammation and injury induced by high-fat diet: possible role of NLRP3 inflammasome activation. J. Pathol. 231 (2013), 342–353.
73. Chen, K., Zhang, J., Zhang, W., Yang, J., Li, K., He, Y., ATP-P2X4 signaling mediates NLRP3 inflammasome activation: a novel pathway of diabetic nephropathy. Int. J. Biochem Cell Biol. 45 (2013), 932–943.
74. Luo, B., Li, B., Wang, W., Liu, X., Xia, Y., Zhang, C., et al. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS One, 9, 2014, e104771.
75. Ozawa, G.Y., Bearse, M.A., Bronson-Castain, K.W., Harrison, W.W., Schneck, M.E., Barez, S., et al. Neurodegenerative differences in the retinas of male and female patients with type 2 DiabetesNeurodegenerative differences in the retina. Invest. Ophthal. Vis. Sci. 53 (2012), 3040–3046.
76. Wang, L., Zhai, Y.Q., Xu, L.L., Qiao, C., Sun, X.L., Ding, J.H., et al. Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice. Exp. Neurol. 251 (2014), 22–29.
77. Latz, E., Xiao, T.S., Stutz, A., Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 13 (2013), 397–411.
78. Camell, C., Goldberg, E., Dixit, V.D., Regulation of Nlrp3 inflammasome by dietary metabolites. Semin. Immunol. 27 (2015), 334–342.
79. Kusunoki, M., Tsutsumi, K., Nakayama, M., Kurokawa, T., Nakamura, T., Ogawa, H., et al. Relationship between serum concentrations of saturated fatty acids and unsaturated fatty acids and the homeostasis model insulin resistance index in Japanese patients with type 2 diabetes mellitus. J. Med. Invest. 54 (2007), 243–247.
80. L'Homme, L., Esser, N., Riva, L., Scheen, A., Paquot, N., Piette, J., et al. Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes/macrophages. J. Lipid Res. 54 (2013), 2998–3008.
81. Sun, C., Fan, S., Wang, X., Lu, J., Zhang, Z., Wu, D., et al. Purple sweet potato color inhibits endothelial premature senescence by blocking the NLRP3 inflammasome. J. Nutr. Biochem. 26 (2015), 1029–1040.
82. Yan, Y., Jiang, W., Spinetti, T., Tardivel, A., Castillo, R., Bourquin, C., et al. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 38 (2013), 1154–1163.
83. Martinez-Micaelo, N., Gonzalez-Abuin, N., Pinent, M., Ardevol, A., Blay, M., Procyanidin B2 inhibits inflammasome-mediated IL-1beta production in lipopolysaccharide-stimulated macrophages. Mol. Nutr. Food Res. 59 (2015), 262–269.
84. Honda, H., Nagai, Y., Matsunaga, T., Okamoto, N., Watanabe, Y., Tsuneyama, K., et al. Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation. J. Leuk. Biol. 96 (2014), 1087–1100.
85. Demidowich, A.P., Davis, A.I., Dedhia, N., Yanovski, J.A., Colchicine to decrease NLRP3-activated inflammation and improve obesity-related metabolic dysregulation. Med. Hypotheses 92 (2016), 67–73.
86. Lamkanfi, M., Mueller, J.L., Vitari, A.C., Misaghi, S., Fedorova, A., Deshayes, K., et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J. Cell Biol. 187 (2009), 61–70.
87. Primiano, M.J., Lefker, B.A., Bowman, M.R., Bree, A.G., Hubeau, C., Bonin, P.D., et al. Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary inflammation. J. Immunol. 197 (2016), 2421–2433.
88. Cookson, B.T., Brennan, M.A., Pro-inflammatory programmed cell death. Trends Microbiol. 9 (2001), 113–114.
89. Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S.R., Jangamreddy, J.R., Mehrpour, M., et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog. Neurobiol. 112 (2014), 24–49.
90. Bergsbaken, T., Fink, S.L., Cookson, B.T., Pyroptosis: host cell death and inflammation. Nat. Rev. Microbiol. 7 (2009), 99–109.
91. Luo, B., Li, B., Wang, W., Liu, X., Xia, Y., Zhang, C., et al. Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model. Cardiovasc. Drugs Ther. Sponsored Int. Soc. Cardiovasc. Pharm. 28 (2014), 33–43.
92. Cocco, M., Miglio, G., Giorgis, M., Garella, D., Marini, E., Costale, A., et al. Design, synthesis, and evaluation of acrylamide derivatives as direct NLRP3 inflammasome isynthesis, and evaluation of acrylamide derivatives as direct NLRP3 inflammasome inhibitors. Chem Med Chem 11:16 (2016), 1790–1803.
93. Hu, Y., Mao, K., Zeng, Y., Chen, S., Tao, Z., Yang, C., et al. Tripartite-motif protein 30 negatively regulates NLRP3 inflammasome activation by modulating reactive oxygen species production. J. Immunol. 185 (2010), 7699–7705.
94. Yang, G., Lee, H.E., Lee, J.Y., A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet. Sci. Rep., 2016, 6.
95. Boriushkin, E., Wang, J.J., Li, J., Bhatta, M., Zhang, S.X., p58IPK suppresses NLRP3 inflammasome activation and IL-1β production via inhibition of PKR in macrophages. Sci. Rep., 2016, 6.
96. Zeller, T., Haase, T., Muller, C., Riess, H., Lau, D., Zeller, S., et al. Molecular characterization of the NLRC4 expression in relation to interleukin-18 levels. Circ. Cardiovasc. Genet. 8 (2015), 717–726.
97. Schmid-Burgk, J.L., Chauhan, D., Schmidt, T., Ebert, T.S., Reinhardt, J., Endl, E., et al. A genome-wide CRISPR (clustered regularly interspaced short palindromic repeats) screen identifies NEK7 as an essential component of NLRP3 inflammasome activation. J. Biol. Chem. 291 (2016), 103–109.